After FDA Rejection, Disc Medicine’s EPP Drug Hits All Goals in Phase 3 Trial

Disc Medicine’s bitopertin succeeded on all primary and secondary endpoints in the APOLLO Phase 3 trial, sending the stock sharply higher.